Roswell Park | Strategic Alliance Partners

Latest from Roswell Park


Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC

April 10, 2022

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

Chemosensitivity Reflects Improved OS Following Adjuvant Chemotherapy in Gastric Cancer

January 26, 2022

Neoadjuvant chemosensitivity was associated with an improvement in overall survival following adjuvant chemotherapy in patients with resectable gastric cancer, according to findings from a cohort study that were published in JAMA Network Open.

Advances in Diagnostics and Therapeutics Propel Interventional Pulmonology Forward

November 23, 2021

Nathaniel Ivanick, MD, FCCP, discusses the evolution of interventional pulmonology, the benefits of robotic navigational bronchoscopy and other novel technologies in the field, and ongoing research that could further push the paradigm forward.